Company

Mediwhale Inc.

Mediwhale uses AI and retinal images to assess cardiovascular risk.

About

Founded in 2016 and based in Seoul, Mediwhale develops AI tools that use retinal images to assess cardiovascular risk. Its DrNoon for CVD device evaluates risk through an eye examination. In March 2026, the company raised KRW 20 billion in Series C funding led by Premier Partners, with participation from KB Investment, QUAD Investment Management, Hana Ventures, AON Investment, Startup Partners, and returning investor IMM Investment.

6Funding rounds

13Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in